Artificial intelligence drug discovery startup Atomwise raises $123M - SiliconANGLE

Artificial intelligence drug discovery startup Atomwise Inc. announced today it has raised $123 million in new funding to scale up its AI technology platform. The Series B round was led by B Capital Group and Sanabil Investments and included DCVC, BV, Tencent, Y Combinator, Dolby Ventures, AME Cloud Ventures and two unnamed top 10 global insurance companies. Founded in 2012, Atomwise uses AI and machine learning algorithms on supercomputers to analyze data related to the creation of new drug molecules. The company uses a neural network called AtomNet to analyze more than 100 million compounds daily to reduce the time and cost involved in drug discovery. The AI is also designed to make predictions about the effectiveness of compounds and possible side effects.